Amazentis
EPFL Innovation Park
Bâtiment C
Lausanne
1015
Website: https://www.amazentis.com/
Email: contact@amazentis.com
About Amazentis
Amazentis is an innovative life science company dedicated to employing breakthrough research and clinical science to bring advanced therapeutic nutrition products to life.YEAR FOUNDED:
2007
LEADERSHIP:
Founders: Patrick Aebischer, Chris Rinsch, André Hoffmann, and Pierre Landolt
Founder: Patrick Aebischer
Founder and CEO: Chris Rinsch
4 articles about Amazentis
-
New Study shows Urolithin A (Mitopure®) Improves Mitochondrial Health, Reduces Joint Cartilage Damage and Alleviates Pain in Osteoarthritis
7/7/2022
Amazentis, a spin-off of the Swiss Federal Institute of Technology (EPFL) pioneering scientific breakthroughs in cellular health and nutrition, announced today that the peer-reviewed journal Aging Cell published new pre-clinical results showing the joint health benefits of gut microbiome postbiotic Urolithin A (UA).
-
Amazentis Launches Timeline™ powered by Mitopure™ A Breakthrough in Cellular Nutrition
7/27/2020
Mitopure™, a first-of-its kind cellular nutrient, clinically proven to boost cellular function and improve muscle strength, is now available to health-striving consumers in Timeline Nutrition products*.
-
Amazentis SA Announces Completion of Series C Financing
3/21/2018
Amazentis Also Announces Initiation of Two Pivotal, Phase 2 Clinical Studies in North America
-
Amazentis Announces Successful Phase IA/IB Study Results In Healthy Elderly Subjects With The Food Metabolite Urolithin A
4/27/2017